Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 25 November 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follo ...
Alligator Bioscience announces final terms of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience presents new data on mitazalimab and ATOR-4066 at SITC 40th Anniversary Annual Meeting
Lund, Sweden – 5 November 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developi ...
Nomination Committee appointed in respect of AGM 2026 in Alligator Bioscience AB
Lund, Sweden, 3 November 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumo ...
Alligator Bioscience AB reports financial results for Q3 2025 and provides a business update
Upcoming rights issue of approx. SEK 120 million (gross), providing 6–9 months of financial runway during 2026, announced 22 October S ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator Bioscience carries out a rights issue of units of approximately SEK 120 million and raises bridge loans
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience granted US patent covering ATOR-4066 bispecific antibody
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno ...
Invitation to Alligator Bioscience’s earnings call on 23 October 2025
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno ...